FDA Drug Name Guidance Is “Up In The Air,” Agency Tells DIA
Executive Summary
FDA may not proceed with a planned guidance for industry on pre-marketing risk assessment of drug names, labeling and packaging, Medical Errors & Technical Support Division Deputy Director Carol Holquist said at the Drug Information Association annual meeting in Washington, D.C. June 16